|
Gene: NDUFA9 |
Gene summary for NDUFA9 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NDUFA9 | Gene ID | 4704 |
Gene name | NADH:ubiquinone oxidoreductase subunit A9 | |
Gene Alias | CC6 | |
Cytomap | 12p13.32 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | Q16795 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4704 | NDUFA9 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.84e-04 | 1.23e-01 | 0.0155 |
4704 | NDUFA9 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.42e-05 | 1.71e-01 | -0.1808 |
4704 | NDUFA9 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.00e-12 | 3.40e-01 | -0.0811 |
4704 | NDUFA9 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.35e-11 | 2.84e-01 | -0.1088 |
4704 | NDUFA9 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.02e-16 | 3.20e-01 | -0.1954 |
4704 | NDUFA9 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.86e-06 | 4.38e-01 | -0.2602 |
4704 | NDUFA9 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.71e-03 | 2.76e-01 | -0.2196 |
4704 | NDUFA9 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.03e-08 | 2.57e-01 | -0.1207 |
4704 | NDUFA9 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.80e-11 | 3.95e-01 | -0.1526 |
4704 | NDUFA9 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.80e-25 | 4.38e-01 | -0.1464 |
4704 | NDUFA9 | HTA11_866_2000001011 | Human | Colorectum | AD | 7.82e-13 | 2.55e-01 | -0.1001 |
4704 | NDUFA9 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.12e-24 | 5.44e-01 | -0.059 |
4704 | NDUFA9 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.52e-10 | 4.65e-01 | -0.1706 |
4704 | NDUFA9 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.12e-05 | 2.59e-01 | -0.2061 |
4704 | NDUFA9 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.34e-04 | 2.80e-01 | -0.1462 |
4704 | NDUFA9 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.83e-08 | 2.90e-01 | -0.0842 |
4704 | NDUFA9 | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.86e-06 | 4.38e-01 | -0.00410000000000005 |
4704 | NDUFA9 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.12e-06 | 3.39e-01 | -0.0179 |
4704 | NDUFA9 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.01e-09 | 2.39e-01 | 0.096 |
4704 | NDUFA9 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.34e-04 | 2.80e-01 | 0.0446 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004277512 | Liver | HCC | mitochondrial ATP synthesis coupled electron transport | 74/7958 | 95/18723 | 1.94e-12 | 9.18e-11 | 74 |
GO:001964612 | Liver | HCC | aerobic electron transport chain | 67/7958 | 87/18723 | 5.43e-11 | 2.00e-09 | 67 |
GO:000612012 | Liver | HCC | mitochondrial electron transport, NADH to ubiquinone | 41/7958 | 51/18723 | 3.41e-08 | 7.61e-07 | 41 |
GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
GO:004218021 | Liver | HCC | cellular ketone metabolic process | 123/7958 | 211/18723 | 2.52e-06 | 3.37e-05 | 123 |
GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
GO:000974912 | Liver | HCC | response to glucose | 121/7958 | 212/18723 | 1.24e-05 | 1.39e-04 | 121 |
GO:000762321 | Liver | HCC | circadian rhythm | 117/7958 | 210/18723 | 7.29e-05 | 6.54e-04 | 117 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:19016611 | Liver | HCC | quinone metabolic process | 26/7958 | 40/18723 | 3.40e-03 | 1.55e-02 | 26 |
GO:002290018 | Oral cavity | OSCC | electron transport chain | 126/7305 | 175/18723 | 6.65e-19 | 8.42e-17 | 126 |
GO:000609118 | Oral cavity | OSCC | generation of precursor metabolites and energy | 286/7305 | 490/18723 | 1.45e-18 | 1.71e-16 | 286 |
GO:000906018 | Oral cavity | OSCC | aerobic respiration | 133/7305 | 189/18723 | 1.79e-18 | 2.02e-16 | 133 |
GO:004533318 | Oral cavity | OSCC | cellular respiration | 153/7305 | 230/18723 | 2.07e-17 | 1.87e-15 | 153 |
GO:003310818 | Oral cavity | OSCC | mitochondrial respiratory chain complex assembly | 75/7305 | 93/18723 | 2.17e-16 | 1.68e-14 | 75 |
GO:004277318 | Oral cavity | OSCC | ATP synthesis coupled electron transport | 75/7305 | 95/18723 | 1.95e-15 | 1.33e-13 | 75 |
GO:004277518 | Oral cavity | OSCC | mitochondrial ATP synthesis coupled electron transport | 75/7305 | 95/18723 | 1.95e-15 | 1.33e-13 | 75 |
GO:002290418 | Oral cavity | OSCC | respiratory electron transport chain | 86/7305 | 114/18723 | 2.43e-15 | 1.63e-13 | 86 |
GO:001598018 | Oral cavity | OSCC | energy derivation by oxidation of organic compounds | 190/7305 | 318/18723 | 4.10e-14 | 2.26e-12 | 190 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05012 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa00190 | Colorectum | AD | Oxidative phosphorylation | 86/2092 | 134/8465 | 2.47e-22 | 2.76e-20 | 1.76e-20 | 86 |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
hsa04714 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa04723 | Colorectum | AD | Retrograde endocannabinoid signaling | 59/2092 | 148/8465 | 2.94e-05 | 2.73e-04 | 1.74e-04 | 59 |
hsa050121 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
hsa052081 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa001901 | Colorectum | AD | Oxidative phosphorylation | 86/2092 | 134/8465 | 2.47e-22 | 2.76e-20 | 1.76e-20 | 86 |
hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
hsa047141 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa049321 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NDUFA9 | SNV | Missense_Mutation | novel | c.764A>T | p.Asp255Val | p.D255V | Q16795 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
NDUFA9 | SNV | Missense_Mutation | c.1006G>A | p.Glu336Lys | p.E336K | Q16795 | protein_coding | deleterious(0) | possibly_damaging(0.884) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD | |
NDUFA9 | SNV | Missense_Mutation | rs750194827 | c.1079N>A | p.Arg360His | p.R360H | Q16795 | protein_coding | tolerated(0.27) | possibly_damaging(0.906) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
NDUFA9 | SNV | Missense_Mutation | rs772826689 | c.139N>A | p.Gly47Arg | p.G47R | Q16795 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NDUFA9 | SNV | Missense_Mutation | c.264N>C | p.Lys88Asn | p.K88N | Q16795 | protein_coding | tolerated(0.51) | benign(0.049) | TCGA-EA-A411-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
NDUFA9 | SNV | Missense_Mutation | c.17A>G | p.Gln6Arg | p.Q6R | Q16795 | protein_coding | tolerated(0.42) | benign(0) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NDUFA9 | SNV | Missense_Mutation | c.1119G>T | p.Lys373Asn | p.K373N | Q16795 | protein_coding | deleterious(0.02) | benign(0.02) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NDUFA9 | SNV | Missense_Mutation | rs772426441 | c.328N>A | p.Ala110Thr | p.A110T | Q16795 | protein_coding | tolerated(0.37) | benign(0.271) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
NDUFA9 | SNV | Missense_Mutation | c.1009N>T | p.Asp337Tyr | p.D337Y | Q16795 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
NDUFA9 | SNV | Missense_Mutation | rs767462328 | c.223C>T | p.Arg75Cys | p.R75C | Q16795 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AZ-6605-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folfox | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4704 | NDUFA9 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 | |
4704 | NDUFA9 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
4704 | NDUFA9 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE |
Page: 1 |